The global induced pluripotent stem cells (iPSCs) market is a rapidly growing sector driven by the increasing demand for personalized medicine, drug discovery, and regenerative medicine applications. iPSCs are adult cells that have been reprogrammed to behave like embryonic stem cells, giving them the potential to differentiate into any cell type in the body. This ability makes iPSCs valuable tools for studying disease mechanisms, screening for potential therapeutics, and developing personalized treatments. The market is characterized by intense competition and a rapidly evolving landscape. Key players in the market include pharmaceutical companies, biotechnology firms, academic research institutions, and contract research organizations. These players are focused on developing innovative iPSC-based products and services to gain a competitive edge in the market.
The Global Induced Pluripotent Stem Cells (iPSCs) Market size is projected to reach USD 2,081.08 million by 2029, with a CAGR of 9.9% during the forecast period of 2022 to 2029.
To know more, visit https://www.databridgemarketresearch.com/reports/global-induced-pluripotent-stem-cells-market
Below are the Top Five Induced Pluripotent Stem Cells (iPSCs) Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
FUJIFILM Corporation
|
Fujifilm Corporation, a renowned Japanese multinational, has a significant presence in the induced pluripotent stem cells (iPSCs) Market. Fujifilm's involvement in this market is primarily through its subsidiary, FUJIFILM Cellular Dynamics, Inc. (FCDI), which is a leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue cells for drug discovery, toxicity testing, and regenerative medicine applications.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In March 2015, FUJIFILM Holdings Corporation acquired Cellular Dynamics International, Inc. which is a bio-venture company. This acquisition helped the company in expanding induced pluripotent stem cells supply business in U.S.
|
|
2.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher Scientific Inc. is a prominent player in the market, offering a wide range of products and services that support iPSC research and applications. Thermo Fisher Scientific provides innovative tools and technologies for cell culture, reprogramming, differentiation, and characterization of iPSCs, enabling researchers to efficiently generate and study these cells for various applications.
|
|
North America, Europe, Asia- Pacific
|
In October 2021, Thermo Fisher Scientific Inc. organized a 5 days stem cell event session from Oct 18-22 virtually. This session aided in discovering incredible insights and advances research with access to scientific presentations from key leaders and prominent researchers all over the world. This thereby enhanced their stem cell research products recognition among customers.
|
|
3.
|
Lonza
|
Lonza offers a wide range of products and services that support iPSC research and applications. Lonza's expertise lies in cell culture and bioprocessing, making it a valuable partner for researchers and companies involved in iPSC research and development. Lonza provides a variety of cell culture media, supplements, and reagents specifically designed for iPSC culture and maintenance.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In February 2021, Lonza announced that they received a delightful Award from the Ethisphere Institute. This Award was given considering the global standards of business integrity and corporate citizenship set by the company. This improved the profile of company and gained more global audiences.
|
|
4.
|
Merck KGaA
|
Merck KGaA, known as EMD Serono in the United States and Canada, is a significant player in the induced pluripotent stem cells (iPSCs) market. The company offers a wide range of products and services that support iPSC research and applications, making it a valuable partner for researchers and companies involved in this field. Merck's portfolio includes cell culture media, supplements, and reagents optimized for iPSC culture and maintenance.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In June 2017, the Merck KGaA made a strategic expansion in distribution alliance with public health England to include the European Bank of induced pluripotent Stem Cells (EBiSC) which is a comprehensive iPS cell bank of more than 300 quality-controlled, disease-relevant, patient-derived human iPSC lines. This helped company in extending their service with wide reach.
|
|
5.
|
Evotec SE
|
Evotec SE offers a range of products and services that support iPSC research and applications. Evotec's expertise lies in drug discovery and development, making it a valuable partner for researchers and companies involved in iPSC-based drug discovery and regenerative medicine. Evotec provides a variety of iPSC-related services, including iPSC reprogramming, differentiation into specific cell types, and disease modeling using patient-derived iPSCs.
|
|
North America and Europe
|
In April 2020, the Evotec SE and panCELLa had signed an agreement for licensing and investment. The company will also receive the license usage of panCELLa’s proprietary iPS cell lines “iACT Stealth Cells™”. This strengthened their position in market.
|
Conclusion
The global induced pluripotent stem cells (iPSCs) market is experiencing rapid growth, driven by factors such as the increasing prevalence of chronic diseases, advancements in regenerative medicine, growing investment in research and development, technological innovations, and rising awareness and acceptance of iPSC-based technologies. iPSCs are playing a crucial role in drug discovery, disease modeling, and personalized medicine, offering promising solutions for conditions with limited therapeutic options. Key players in the market are focused on developing innovative iPSC-based products and services to capitalize on this growing market opportunity. Overall, the iPSC market is expected to continue its growth trajectory, shaping the future of medicine and healthcare.
